ALPINE IMMUNE SCIENCES, INC. Contracts & Agreements

Agreement and Plan of Merger by and among Alpine Immune Sciences, Inc., Vertex Pharmaceuticals Incorporated and Adams Merger Sub, Inc., dated April 10, 2024 (Filed With SEC on April 10, 2024)

Form of Tender and Support Agreement (Filed With SEC on April 10, 2024)

Form of Frazier Tender and Support Agreement (Filed With SEC on April 10, 2024)

Description of Capital Stock (Filed With SEC on March 20, 2024)

Non-Employee Director Compensation Guidelines (Filed With SEC on March 20, 2024)

Letter Agreement, dated December 20, 2023, between Alpine Immune Sciences Inc. and AbbVie Global Enterprises Ltd. amending the Option and License Agreement, dated June 17, 20 (Filed With SEC on March 20, 2024)

Alpine Immune Sciences, Inc. Change of Control and Severance Policy, as amended and restated effective January 4, 2024 (Filed With SEC on January 5, 2024)

Employment Agreement, dated as of September 20, 2023, by and between (Filed With SEC on November 14, 2023)

Form of Stand-Alone Inducement Stock Option Grant between the Registrant and (Filed With SEC on November 14, 2023)

Underwriting Agreement, dated (Filed With SEC on November 8, 2023)

Form of Pre-Funded Warrant (Filed With SEC on November 8, 2023)

Employment Agreement, dated as of January 1, 2020, by and between the Registrant and Remy Durand M.D., Ph.D (Filed With SEC on May 11, 2023)

Description of Capital Stock (Filed With SEC on March 23, 2023)

Form of Stand-Alone Inducement Stock Option Grant between the Company and Andrew Sandler (Filed With SEC on November 14, 2022)

Underwriting Agreement, dated September 20, 2022, by and among Alpine Immune Sciences, Inc. and Morgan Stanley & Co. LLC, SVB Securities LLC and Cowen and Company, LLC, as... (Filed With SEC on September 21, 2022)

Executive Employment Agreement, dated as of May 27, 2022, by and between Alpine Immune Sciences, Inc. and Andrew Sandler (Filed With SEC on August 11, 2022)

Letter Agreement, dated April 12, 2022, between Alpine Immune Sciences Inc. and AbbVie Global Enterprises Ltd. amending the Option and License Agreement, dated June 17, 2017, by... (Filed With SEC on August 11, 2022)

Separation Agreement, dated as of October 8, 2021, by and between the Registrant and Zelanna Goldberg (Filed With SEC on March 17, 2022)

License and Collaboration Agreement, dated December 15, 2021 by and between Alpine Immune Sciences, Inc. and Horizon Therapeutics Ireland DAC (Filed With SEC on March 17, 2022)

Stock Purchase Agreement, dated December 15, 2021 by and between Alpine Immune Sciences, Inc. and Horizon Therapeutics Ireland DAC (Filed With SEC on March 17, 2022)

Securities Purchase Agreement, dated September (Filed With SEC on September 15, 2021)

Registration Rights Agreement, dated September (Filed With SEC on September 15, 2021)

Form of Prefunded Warrant to Purchase Common Stock (Filed With SEC on September 15, 2021)

Exchange Agreement, dated September 14, 2021, by and between the Company and Frazier Life Sciences VIII, L.P (Filed With SEC on September 15, 2021)

Form of Stand-Alone Inducement Stock Option Grant between the Company and Zelanna Goldberg (Filed With SEC on August 10, 2021)

Executive Employment Agreement, dated June 1, 2021, by and between the Company and Zelanna Goldberg (Filed With SEC on August 10, 2021)

Sales Agreement, dated as of July (Filed With SEC on July 2, 2021)

Description of Capital Stock (Filed With SEC on March 18, 2021)

Non-Employee Director Compensation Guidelines (Filed With SEC on March 18, 2021)

Option and License Agreement, dated June 17, 2020, by and between the Company and AbbVie Ireland Unlimited Company (Filed With SEC on August 11, 2020)

Securities Purchase Agreement, dated July 24, 2020, by and among the Company and the Purchasers (Filed With SEC on July 24, 2020)

Registration Rights Agreement, dated July 24, 2020, by and among the Company and the Purchasers (Filed With SEC on July 24, 2020)

Form of Warrant to Purchase Common Stock (Filed With SEC on July 24, 2020)

Form of Prefunded Warrant to Purchase Common Stock (Filed With SEC on July 24, 2020)

2018 Equity Incentive Plan, as amended (Filed With SEC on June 17, 2020)

Description of Capital Stock (Filed With SEC on March 30, 2020)

Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan (Filed With SEC on January 27, 2020)

Warrant to Purchase Common Stock, dated August 26, 2019, by and between Alpine Immune Sciences, Inc. and Silicon Valley Bank (Filed With SEC on August 28, 2019)

Amended and Restated Loan and Security Agreement, dated August 26, 2019, by and among Alpine Immune Sciences, Inc., AIS Operating Co., Inc. and Silicon Valley Bank (Filed With SEC on August 28, 2019)

Separation Agreement, dated April 24, 2019, by and between the Company and Mark Litton (Filed With SEC on August 13, 2019)

Lease Agreement, dated March 14, 2019, by and between the Company and ARE-Seattle No. 28, LLC (Filed With SEC on May 9, 2019)

Alpine Immune Sciences, Inc. Executive Incentive Compensation Plan (Filed With SEC on April 1, 2019)

Alpine Immune Sciences, Inc. Non-Employee Director Compensation Guidelines (Filed With SEC on April 1, 2019)

License and Research Agreement Amendment No. 2 by and between AIS Operating Co., Inc. and Kite Pharma, Inc., effective as of October 17, 2018 (Filed With SEC on March 18, 2019)

Registration Rights Agreement, dated January 15, 2019, by and among the Company and the Purchasers (Filed With SEC on January 16, 2019)

Form of Warrant to Purchase Common Stock (Filed With SEC on January 16, 2019)

Securities Purchase Agreement, dated January 15, 2019, by and among the Company and the Purchasers (Filed With SEC on January 16, 2019)

Form of Stand-Alone Inducement Stock Option Grant (Filed With SEC on August 6, 2018)

Executive Employment Agreement, dated August 6, by and between the Company and Mark Litton (Filed With SEC on August 6, 2018)

Alpine Immune Sciences, Inc. 2018 Equity Incentive Plan (Filed With SEC on June 14, 2018)

Form of Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on June 14, 2018)

Equity Distribution Agreement, dated as of June 11, 2018, between Alpine Immune Sciences, Inc. and Piper Jaffray & Co (Filed With SEC on June 11, 2018)

Non-Employee Director Compensation Guidelines (Filed With SEC on May 14, 2018)

Form of Common Stock Certificate of the Registrant (Filed With SEC on March 28, 2018)

Warrant to Purchase Shares, dated December 16, 2016, by and between Alpine Immune Sciences, Inc. and Silicon Valley Bank (Filed With SEC on March 28, 2018)

Form of Warrant to Purchase Shares of Common Stock issued to certain service providers on April 12, 2017 pursuant to the Amended and Restated 2015 Stock Plan, as amended (Filed With SEC on March 28, 2018)

Loan and Security Agreement, dated December 16, 2016, by and among Alpine Immune Sciences, Inc. and Silicon Valley Bank (Filed With SEC on March 28, 2018)

Employment Agreement, dated as of March 14, 2017, by and between the Registrant and Mitchell H. Gold, M.D (Filed With SEC on March 28, 2018)

Employment Agreement, dated as of January 1, 2018, by and between the Registrant and Mitchell H. Gold, M.D (Filed With SEC on March 28, 2018)

Employment Agreement, dated as of April 1, 2017, by and between the Registrant and Paul Rickey (Filed With SEC on March 28, 2018)

Employment Agreement, dated as of January 1, 2018, by and between the Registrant and Paul Rickey (Filed With SEC on March 28, 2018)

Employment Agreement, dated as of August 14, 2016, by and between the Registrant and Stanford Peng, M.D., Ph.D (Filed With SEC on March 28, 2018)

Employment Agreement, dated as of January 1, 2018 , by and between the Registrant and Stanford Peng, M.D., Ph.D (Filed With SEC on March 28, 2018)

Change of Control and Severance Policy (Filed With SEC on December 11, 2017)

Form of Executive Employment Agreement (Filed With SEC on December 11, 2017)

License and Research Agreement by and between Alpine Immune Sciences, Inc. and Kite Pharma, Inc., effective as of October 26, 2015 (Filed With SEC on October 24, 2017)

License and Research Agreement Amendment No. 1 by and between AIS Operating Co., Inc. and Kite Pharma, Inc., effective as of October 20, 2017 (Filed With SEC on October 24, 2017)

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: NIVALIS THERAPEUTICS, INC., a Delaware corporation; NAUTILUS MERGER SUB, INC., a Delaware corporation; and ALPINE IMMUNE... (Filed With SEC on April 18, 2017)

FORM OF SUPPORT AGREEMENT (Filed With SEC on April 18, 2017)

CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (Filed With SEC on February 13, 2017)

AMENDMENT to the EMPLOYMENT AGREEMENT between Nivalis Therapeutics, Inc. and Janice M. Troha (“Employee”) (Filed With SEC on February 13, 2017)

Nivalis Therapeutics, Inc. 3122 Sterling Circle, Suite 200, Boulder, CO 80301 (Filed With SEC on February 13, 2017)

AMENDMENT to the EMPLOYMENT AGREEMENT between Nivalis Therapeutics, Inc. and R. Michael Carruthers (“Employee”) (Filed With SEC on February 13, 2017)

Nivalis Therapeutics, Inc. 3122 Sterling Circle, Suite 200, Boulder, CO 80301 (Filed With SEC on February 13, 2017)

AMENDMENT to the EMPLOYMENT AGREEMENT between Nivalis Therapeutics, Inc. and David M. Rodman, M.D. (“Employee”) (Filed With SEC on February 13, 2017)

CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (Filed With SEC on February 13, 2017)

AMENDMENT to the EMPLOYMENT AGREEMENT between Nivalis Therapeutics, Inc. and Jon Congleton (“Employee”) (Filed With SEC on February 13, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on May 3, 2016)

NOTICE OF INDUCEMENT STOCK OPTION GRANT NIVALIS THERAPEUTICS, INC. (Filed With SEC on May 3, 2016)

NOTICE OF RESTRICTED STOCK UNIT INDUCEMENT GRANT NIVALIS THERAPEUTICS, INC. (Filed With SEC on May 3, 2016)

THIRD AMENDMENT TO LEASE (Filed With SEC on March 8, 2016)

Nivalis Therapeutics, Inc. Non-Employee Director Compensation Guidelines Effective July 16, 2015 (Filed With SEC on August 4, 2015)

[Number of Shares] Nivalis Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 3, 2015)

NIVALIS THERAPEUTICS, INC. a Delaware Corporation Incorporated on July 31, 2012 Common Stock Par Value: $0.001 (Filed With SEC on May 13, 2015)

N30 PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on May 13, 2015)

SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on May 13, 2015)

NIVALIS THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN EFFECTIVE AS OF , 2015 (Filed With SEC on May 13, 2015)

N30 PHARMACEUTICALS, INC. 2012 STOCK INCENTIVE PLAN (Filed With SEC on May 13, 2015)

N30 PHARMACEUTICALS, INC. 2012 STOCK INCENTIVE PLAN STOCK OPTION AGREEMENT (Filed With SEC on May 13, 2015)

NIVALIS THERAPEUTICS, INC. EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on May 13, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on May 13, 2015)

AMENDMENT to the EMPLOYMENT AGREEMENT between Nivalis Therapeutics, Inc. (formerly known as N30 Pharmaceuticals, Inc.) and Jon Congleton (Employee) (Filed With SEC on May 13, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on May 13, 2015)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on May 13, 2015)

AMENDMENT to the EMPLOYMENT AGREEMENT Effective November 1, 2012 between Nivalis Therapeutics, Inc. (formerly known as N30 Pharmaceuticals, Inc.) and Janice M. Troha (Employee) (Filed With SEC on May 13, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on May 13, 2015)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on May 13, 2015)

AMENDMENT to the EMPLOYMENT AGREEMENT Effective November 1, 2012 between Nivalis Therapeutics, Inc. (formerly known as N30 Pharmaceuticals, Inc.) and Sherif E. Gabriel (Employee) (Filed With SEC on May 13, 2015)

LEASE (Filed With SEC on May 13, 2015)

FIRST AMENDMENT TO LEASE (Filed With SEC on May 13, 2015)

SECOND AMENDMENT TO LEASE (Filed With SEC on May 13, 2015)

NIVALIS THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on May 13, 2015)

Category

Industry

Companies

Contracts

ALPINE IMMUNE SCIENCES, INC. Contracts & Agreements